Compared with the control group, mean levels of CSF SV2A in the aMCI and AD groups were significantly reduced by approximately 26.91% (p = 0.0013) and 56.96% (p < 0.0001), respectively. This evidence concerns the gene SV2A and Alzheimer disease.